Revelation Biosciences, Inc. (REVB) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the REVB SEC filings page.
This page shows Revelation Biosciences, Inc. (REVB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revelation remains development-led: losses consume cash, while financing inflows—not sales—are the reported source supporting operations.
The 2025 operating loss narrowed to$9.1M from$15.0M in 2024, while operating cash outflow narrowed to$8.3M from$18.3M . That closer relationship between accounting loss and cash use indicates cash conversion improved, rather than the latest result being supported mainly by non-operating accounting effects.
The current ratio rose from 3.4x to 5.4x as total assets increased from
With no revenue reported, the business cannot yet be assessed through product-level margins. Instead, its cost base is visibly development-led: 2025 research and development of
Financial Health Signals
Revelation Biosciences, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Revelation Biosciences, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Revelation Biosciences, Inc. reported a net loss of $8.9M while operations used $8.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Revelation Biosciences, Inc.'s EBITDA was -$3.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 48.9% from the same quarter a year earlier. Against the prior quarter it is down 18.4%.
Revelation Biosciences, Inc. reported -$3.3M in net income in Q2 2026. This represents a decrease of 36.0% from the same quarter a year earlier. Against the prior quarter it is down 10.4%.
Not reported for Q2 2026.
Cash & Balance Sheet
Revelation Biosciences, Inc. recorded an outflow of $2.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. Against the prior quarter it is up 21.0%.
Revelation Biosciences, Inc. held $11.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Revelation Biosciences, Inc.'s ROE was -33.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 30.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 9.8 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Revelation Biosciences, Inc. invested $1.9M in research and development in Q2 2026. This represents an increase of 45.6% from the same quarter a year earlier. Against the prior quarter it is up 39.3%.
Revelation Biosciences, Inc. invested $40K in capex in Q2 2026, funding long-term assets and infrastructure. Against the prior quarter it is down 44.9%.
Not reported for Q2 2026.
REVB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.9M+45.6% | $1.4M+60.3% | N/A | $923K+11.1% | $1.3M-5.5% | $859K+19.7% | N/A | $831K-49.7% |
| SG&A Expenses | $1.7M+52.5% | $1.7M+38.8% | N/A | $1.0M+5.6% | $1.1M+1.4% | $1.2M+4.4% | N/A | $966K-14.3% |
| Operating Income | -$3.7M-48.8% | -$3.1M-47.6% | N/A | -$1.9M-8.1% | -$2.5M+2.4% | -$2.1M-10.1% | N/A | -$1.8M+35.3% |
| EBITDA | -$3.7M-48.9% | -$3.1M-47.8% | N/A | -$1.9M-8.2% | -$2.5M+2.4% | -$2.1M-10.1% | N/A | -$1.8M+35.4% |
| Interest Expense | $82K+317.6% | N/A | N/A | N/A | $20K | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | $0 | N/A | $0 | N/A | $0 |
| Net Income | -$3.3M-36.0% | -$3.0M-46.7% | N/A | -$1.9M+14.9% | -$2.4M+70.9% | -$2.1M+23.5% | N/A | -$2.2M+14.7% |
| EPS (Basic) | -$0.87+96.9% | -$2.71+89.3% | -$14.19+98.0% | -$1.77+95.6% | -$28.04+88.6% | -$25.34+35.6% | -$698.11-6777.9% | -$40.15-303.9% |
| EPS (Diluted) | -$0.87 | -$2.71 | -$14.19 | -$1.77 | -$28.04 | -$25.34+35.6% | -$698.11 | -$40.15 |
| Diluted Shares (Avg) | 4M | 3M | N/A | 3M | 200,668 | 80,943+18.8% | N/A | 55,832 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
REVB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $12.5M+131.7% | $15.0M+278.9% | $11.6M+74.9% | $12.9M+90.7% | $5.4M-56.0% | $4.0M-73.0% | $6.6M-45.8% | $6.7M-52.6% |
| Current Assets | $11.7M+118.0% | $14.2M+261.7% | $10.8M+64.7% | $12.8M+92.7% | $5.4M-56.1% | $3.9M-73.1% | $6.6M-46.0% | $6.7M-52.9% |
| Cash & Equivalents | $11.5M+121.9% | $14.1M+281.0% | $10.7M+64.6% | $12.7M+94.3% | $5.2M-57.1% | $3.7M-74.5% | $6.5M-45.8% | $6.5M-53.3% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $2.4M+54.9% | $2.1M+88.6% | $2.7M+42.2% | $1.9M-54.4% | $1.6M-85.9% | $1.1M-79.2% | $1.9M-65.6% | $4.1M-24.7% |
| Current Liabilities | $1.9M+19.8% | $1.4M+30.1% | $2.0M+4.4% | $1.9M-54.4% | $1.6M-85.9% | $1.1M-79.2% | $1.9M-65.6% | $4.1M-24.7% |
| Non-Current Liabilities | $551K | $638K | $724K | $0 | $0 | $0 | $0 | $0 |
| Total Equity | $10.1M+163.1% | $13.0M+350.9% | $8.9M+88.2% | $11.0M+311.5% | $3.8M+235.5% | $2.9M-69.6% | $4.7M-29.2% | $2.7M-69.7% |
| Retained Earnings | -$55.8M-23.9% | -$52.4M-23.2% | -$49.4M-22.0% | -$46.9M-21.0% | -$45.0M-23.2% | -$42.6M-51.2% | -$40.5M-59.1% | -$38.8M-66.7% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
REVB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.6M-33.2% | -$3.2M-15.0% | -$2.0M+47.5% | -$1.6M+82.8% | -$1.9M+22.6% | -$2.8M+1.5% | -$3.7M-87.1% | -$9.3M-439.2% |
| Depreciation & Amortization | $8K+15.1% | $7K-0.2% | $6K-19.0% | $7K-6.3% | $7K0.0% | $7K+15.3% | $7K+15.3% | $7K+15.3% |
| Stock-Based Compensation | $401K+45881.3% | $471K+110.8% | N/A | $874-97.3% | $873-97.3% | $223K+596.3% | N/A | $32K0.0% |
| Capital Expenditures | $40K | $72K | N/A | N/A | N/A | N/A | -$18K | $18K |
| Free Cash Flow | -$2.6M | -$3.3M | N/A | N/A | N/A | N/A | -$3.8M | -$9.3M-440.3% |
| Investing Cash Flow | -$40K | -$72K | N/A | N/A | N/A | N/A | $18K | -$18K |
| Financing Cash Flow | -$34K | $6.7M | -$41K-101.1% | $9.1M+143.8% | N/A | N/A | $3.7M | $3.7M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
REVB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -33.0%+30.9pp | -23.2%+48.0pp | N/A | -17.3%+66.5pp | -63.9%+671.8pp | -71.2%-42.9pp | N/A | -83.8%-54.0pp |
| Return on Assets | -26.6%+18.7pp | -20.0%+31.7pp | N/A | -14.8%+18.4pp | -45.3%+23.1pp | -51.7%-33.4pp | N/A | -33.3%-14.8pp |
| Current Ratio | 6.21+2.8x | 10.02+6.4x | 5.41+2.0x | 6.92+5.3x | 3.42+2.3x | 3.61+0.8x | 3.43+1.2x | 1.64-1.0x |
| Debt-to-Equity | 0.24-0.2x | 0.16-0.2x | 0.31-0.1x | 0.17-1.4x | 0.41-9.3x | 0.38-0.2x | 0.41-0.4x | 1.52+0.9x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Revelation Biosciences, Inc. REVB | FY2025 | N/A | -$8.9M | N/A | $3.0M | — |
| Qualigen Therapeutics, Inc. QLGN | FY2025 | N/A | -$17.0M | N/A | $6.5M | — |
| PMGC Holdings Inc. ELAB | FY2025 | $590K | -$7.7M | N/A | $2.7M | — |
| Galecto, Inc. GLTO | FY2025 | N/A | -$209.8M | N/A | $1.7B | — |
| Entero Therapeutics, Inc. ENTO | FY2025 | $36K | -$6.4M | N/A | $10.1M | — |
| Silexion Therapeutics Corp SLXN | FY2025 | $155K | -$11.9M | N/A | $1.4M | — |
Where Revelation Biosciences, Inc. Ranks
Frequently Asked Questions
Is Revelation Biosciences, Inc. profitable?
No, Revelation Biosciences, Inc. (REVB) reported a net income of -$8.9M in fiscal year 2025.
What is Revelation Biosciences, Inc.'s EBITDA?
Revelation Biosciences, Inc. (REVB) had EBITDA of -$9.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Revelation Biosciences, Inc.'s return on equity (ROE)?
Revelation Biosciences, Inc. (REVB) has a return on equity of -100.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Revelation Biosciences, Inc.'s operating cash flow?
Revelation Biosciences, Inc. (REVB) recorded an outflow of $8.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Revelation Biosciences, Inc.'s total assets?
Revelation Biosciences, Inc. (REVB) had $11.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Revelation Biosciences, Inc. spend on research and development?
Revelation Biosciences, Inc. (REVB) invested $4.1M in research and development during fiscal year 2025.
What is Revelation Biosciences, Inc.'s current ratio?
Revelation Biosciences, Inc. (REVB) had a current ratio of 5.41 as of fiscal year 2025, which is generally considered healthy.
What is Revelation Biosciences, Inc.'s debt-to-equity ratio?
Revelation Biosciences, Inc. (REVB) had a debt-to-equity ratio of 0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Revelation Biosciences, Inc.'s return on assets (ROA)?
Revelation Biosciences, Inc. (REVB) had a return on assets of -77.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Revelation Biosciences, Inc.'s P/E ratio?
Revelation Biosciences, Inc. (REVB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $3.0M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Revelation Biosciences, Inc.'s price-to-sales ratio?
Revelation Biosciences, Inc. (REVB) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $3.0M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Revelation Biosciences, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Revelation Biosciences, Inc. (REVB) held $10.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.3M over that year. Dividing the one by the other, the reported balance equals about 16 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Revelation Biosciences, Inc.'s Piotroski F-Score?
Revelation Biosciences, Inc. (REVB) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Revelation Biosciences, Inc.'s earnings high quality?
Revelation Biosciences, Inc. (REVB) reported a net loss of $8.9M while operations used $8.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.